Topic: Clinical Trial Results
Ocular Therapeutix’s drug-eluting tear duct plug for glaucoma fell just short of the primary endpoint of its first phase 3 trial.
The FDA has quashed ImmunoGen’s hopes of filing for approval of mirvetuximab soravtansine on the strength of a failed phase 3.
Melior Pharmaceuticals reported positive “signals” in its latest diabetes test, but dosing mix-ups mean we don’t have a clear picture of what happened.
Cytokinetics’ reldesemtiv failed to beat placebo on a lung function test, but the company thinks a post hoc analysis shows a path forward.
The durability of bb2121 in multiple myeloma could be a concern, as the CAR-T is a key asset in BMS' $74 billion buyout of Celgene.
The vast majority of universities are failing to comply with EU rules on the reporting of clinical trial results.
Merrimack is dumping another cancer therapy and swinging the ax across its already severely depleted workforce.
Aldeyra Therapeutics aced a phase 3 trial of reproxalap for allergic conjunctivitis, sending its stock up at least 66% in premarket trading.
Join Dr. David Gosalvez to see how R&D productivity can be improved in three critical areas: Lead Discovery, Screening and data capture.
Supernus’ two phase 3 studies in children with ADHD hit their primary endpoints but didn’t wow investors worried about established generics.